- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02318927
A Responsive Closed-Loop Approach to Treat Freezing of Gait in Parkinson's Disease
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
As a participant in the study you will have the following procedure performed:
A series of questions by interview, questionnaires, and checklists will be collected. In addition, basic information (such as age, sex, race) and psychiatric, medical, and family history, physical and neurological exam that will include measuring vital signs (heart rate and blood pressure). There will be a "Falls Diary' to complete (an account of falling incidents and the details). Specific testing will be done to evaluate the gait and balance which will be repeated throughout the study. A psychiatric evaluation of mood and emotion will be performed including a detailed psychological testing, consisting of perception, learning, and memory. These psychological assessments will be repeated at every study visit. An MRI and a CT scan will be performed to make sure of the exact location of the DBS implant. The study will end in 24 months.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Florida
-
Gainesville, Florida, United States, 32607
- University of Florida Center for Movement Disorders and Neurorestoration
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- A clinical diagnosis of idiopathic PD, without a previous DBS operation
- Must be deemed appropriate for a GPi DBS operation by the interdisciplinary screening team (GPi must be the target chosen as most appropriate for treatment of their PD to qualify for this study)
- Age 30-75 years (must meet UK Brain Bank criteria for diagnosis of idiopathic Parkinson's disease).
- Experiencing significant gait and postural instability despite optimal pharmacologic management (Hoehn and Yahr Stage II or greater in the on state). 5. Best medication "on" does not reveal meaningful improvement in posture scores (Pull Test). Patients must be challenged in person with a suprathreshold dose of levodopa (1.5 times optimized regular dose of levodopa) and must have poor or no improvement in postural stability.
6. Patients must possess a clinical history of gait freezing > 2 episodes per month, to be included, participants must also score > 1 on item #3 of the Freezing of Gait (FOG) Questionnaire and exhibit five or more FoG episodes during the provocation protocol in on or off state.
7. L-dopa responsive with clearly defined "on" periods. 8. Willingness and ability to cooperate during conscious operative procedure, as well as during post-surgical evaluations, adjustments of medications and stimulator settings.
Exclusion Criteria:
- Clinically significant medical disease that would increase the risk of developing pre- or postoperative complications. Clinically significant medical disease includes uncontrolled systemic hypertension with values above 170/100mmHg; cardiac or pulmonary disease; uncorrected coagulation abnormalities or need for therapeutic anticoagulation which cannot be interrupted; any condition that would render the patient unable to safely cooperate with the study tests as judged by the screening physician.
- Evidence of secondary or atypical parkinsonism.
- Other neurological and musculoskeletal impairments that would negatively influence postural stability
- Past MRI scan with significant evidence of brain atrophy or other abnormalities. 5. Dementia as evidenced by impairment in two neuropsychological domains and a Mattis Dementia Score <130.
6. A major untreated psychiatric disorder as revealed on psychiatric exam at screening, and a Beck Depression Inventory Score >14.
7. Subjects with a history of seizures. 8. Subjects who may require repeat MRI scans. 9. Subjects with a history of a cranial neurosurgical procedure. 10. Subjects with metal in the head or another implanted stimulator (e.g. vagus nerve stimulator, spinal cord stimulator, pacemaker, cochlear implant, etc).
11. Subjects who require treatment with Electroconvulsive therapy (ECT) or repetitive Transcranial Magnetic Stimulation (rTMS).
12. Pregnant or nursing women or women who wish to become pregnant will be excluded.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Device Feasibility
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Deep Brain Stimulation
Deep Brain Stimulation (DBS) of Globus Pallidum plus Pedunculopontine Nucleus, including lead implant and battery placement.
Magnetic Resonance Imaging and Computed Tomography (CT) scan will be obtained prior to implant.
Measurement of number of Freezing of Gait (FoG) episodes during a FoG test at a lab.
Other measures include freezing of gait questionnaire, gait and falls questionnaire, activities/balance confidence scale, Parkinson's disease quality of life questionnaire, Unified Parkinson's Disease Rating Scale physiology collection and sensor testing, adverse event recording, falls diaries, tracking use of assistive devices, gait and balance testing, and neuropsychological, neurosurgical, neurological, and physical exams.
|
Deep Brain Stimulation (DBS) of Globus Pallidum plus Pedunculopontine Nucleus, including lead implant and battery placement.
Magnetic Resonance Imaging and Computed Tomography (CT) scan will be obtained prior to implant.
Measurement of number of Freezing of Gait (FoG) episodes during a FoG test at a lab.
Other measures include freezing of gait questionnaire, gait and falls questionnaire, activities/balance confidence scale, Parkinson's disease quality of life questionnaire, Unified Parkinson's Disease Rating Scale physiology collection and sensor testing, adverse event recording, falls diaries, tracking use of assistive devices, gait and balance testing, and neuropsychological, neurosurgical, neurological, and physical exams.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of Freezing of Gait (FoG) episodes in the laboratory during the FoG battery
Time Frame: Change from Baseline to 6 Months
|
Change from Baseline to 6 Months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of adverse events (AE's) .
Time Frame: Change from Baseline to 24 Months
|
The DSMB will review all adverse events (AE's) in real time.
The device related AE definition will include both therapy and procedure related AE's.
The Data Safety Monitoring Board (DSMB) will evaluate the study at least every 6 months and have the power to terminate the study for safety reasons.
|
Change from Baseline to 24 Months
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Freezing of gait questionnaire
Time Frame: Change from Baseline to 6 Months
|
Change from Baseline to 6 Months
|
Gait and falls questionnaire
Time Frame: Change from Baseline to 6 Months
|
Change from Baseline to 6 Months
|
Activities/balance confidence scale
Time Frame: Change from Baseline to 6 Months
|
Change from Baseline to 6 Months
|
Parkinson's disease quality of life questionnaire
Time Frame: Change from Baseline to 6 Months
|
Change from Baseline to 6 Months
|
Unified Parkinson's Disease Rating Scale (UPDRS) Part 3 to assess Parkinson's disease symptom severity on medication and on stimulation
Time Frame: Change from Screening to 6 Months
|
Change from Screening to 6 Months
|
Number of falls reported on Falls Diary
Time Frame: Change from Baseline to 6 Months
|
Change from Baseline to 6 Months
|
Unified Parkinson's Disease Rating Scale (UPDRS) Part 3 to assess Parkinson's disease symptom severity off medication and on stimulation
Time Frame: Change from Screening to 6 Months
|
Change from Screening to 6 Months
|
Total Unified Parkinson's Disease Rating Scale (UPDRS) to assess Parkinson's disease symptom severity on medication and on stimulation
Time Frame: Change from Screening to 6 Months
|
Change from Screening to 6 Months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Michael S Okun, MD, University of Florida
Publications and helpful links
General Publications
- Molina R, Hass CJ, Sowalsky K, Schmitt AC, Opri E, Roper JA, Martinez-Ramirez D, Hess CW, Foote KD, Okun MS, Gunduz A. Neurophysiological Correlates of Gait in the Human Basal Ganglia and the PPN Region in Parkinson's Disease. Front Hum Neurosci. 2020 Jun 4;14:194. doi: 10.3389/fnhum.2020.00194. eCollection 2020.
- Tahafchi P, Molina R, Roper JA, Sowalsky K, Hass CJ, Gunduz A, Okun MS, Judy JW. Freezing-of-Gait detection using temporal, spatial, and physiological features with a support-vector-machine classifier. Annu Int Conf IEEE Eng Med Biol Soc. 2017 Jul;2017:2867-2870. doi: 10.1109/EMBC.2017.8037455.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB201400951
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinsons Disease
-
University of California, San FranciscoNovartisCompletedParkinsons Disease With Dementia | Parkinsons Disease With Mild to Moderate Memory and/or Thinking ProblemsUnited States
-
Diskapi Teaching and Research HospitalCompleted
-
Hoffmann-La RocheProthena Biosciences LimitedActive, not recruitingParkinsons DiseaseUnited States, United Kingdom, Canada, France, Luxembourg, Poland, Spain, Italy, Austria
-
NYU Langone HealthTerminatedParkinsons DiseaseUnited States
-
Beth Israel Deaconess Medical CenterCompletedParkinsons DiseaseUnited States
-
University of VirginiaCompletedParkinsons DiseaseUnited States
-
Institut National de la Santé Et de la Recherche...Unknown
-
InSightecRecruitingMovement Disorders | Parkinsons Disease | NeurologyUnited States, Japan
-
University of Colorado, DenverMichael J. Fox Foundation for Parkinson's ResearchCompleted
Clinical Trials on Deep Brain Stimulation
-
Abbott Medical DevicesTerminatedDepressive Disorder, Major | Unipolar DepressionUnited States, Canada, United Kingdom
-
Zhiqi MaoRecruitingParkinson's Disease | Executive Function | Electroencephalogram | Functional Near - Infrared SpectroscopyChina
-
Ali Rezai, MDCompleted
-
University Hospital Inselspital, BerneCompletedMovement Disorder | Urinary Tract DiseaseSwitzerland
-
University of MinnesotaRecruitingParkinson DiseaseUnited States
-
NewronikaTerminatedParkinson DiseaseItaly
-
Butler HospitalMedtronicCompletedObsessive-Compulsive DisorderUnited States
-
Qilu Hospital of Shandong UniversityRecruiting
-
University of Sao Paulo General HospitalUnknownCerebellar AtaxiaBrazil
-
Boston Scientific CorporationCompletedParkinson's DiseaseUnited States